James Signorovitch
Education
Ph.D., biostatistics, Harvard University; B.A., biology, Cornell University
Summary of Experience
Dr. Signorovitch advises life sciences companies on data analytics for business critical research and decision making. He has broad experience leading the strategic development and implementation of analytics across the product life cycle, from early-phase clinical studies to market access and real-world evidence generation. Dr. Signorovitch’s practice areas span trial design, multi-stakeholder collaborations, natural history studies, regulatory interactions, health economic modeling, global reimbursement submissions, policy evaluation, real-world evidence development, individualized medicine, predictive analytics, and due diligence for acquisitions. He has particular expertise in developing and applying new methodologies to address health care research challenges, and in designing analytics platforms to enhance collaborative research and decision making. Dr. Signorovitch’s work has been used to inform clinical regulators and health care payers in US and global markets, published in peer-reviewed journals, and presented at clinical and economic research conferences. Prior to joining Analysis Group, Dr. Signorovitch was a research fellow at the Harvard-MIT Division of Health Sciences and Technology.
-
Projected Impact of Omidubicel-onlv on Racial/Ethnic Disparities in Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Outcomes in Hematologic Malignancies
Advances in Therapy, Vol. 41 (2024), pp. 1637–1651
2024Khera N, Edwards ML, Song Y, Sun R, Manghani R, Shin H, Simantov R, Signorovitch J, Sivaraman S, Gergis U
-
Real-World Neoadjuvant Treatment Patterns and Outcomes in Resected Non-Small-Cell Lung Cancer
Clinical Lung Cancer, 2024
2024Donington J, Hu X, Zhang S, Song Y, Arunachalam A, Chirovsky D, Gao C, Lerner A, Jiang A, Signorovitch J, Samkari A
-
Pathway for Development and Validation of Multi-domain Endpoints for Amyloid Light Chain (AL) Amyloidosis
Therapeutic Innovation & Regulatory Science, 2024
2024Signorovitch J, Zhang J, Brown D, Dunnmon P, Xiu L, Done N, Hsu K, Barbachano Y, Lousada I
-
Treatment patterns of patients with worsening heart failure with reduced ejection fraction
ESC Heart Failure, 2024
2024Greene SJ, Gaggin HK, Zhou M, Bash LD, Lautsch D, Djatche L, Song Y, Signorovitch J, Stevenson AS, Blaustein RO, Butler J
-
Epidemiology and economic burden of Von Hippel-Lindau Disease-associated central nervous system hemangioblastomas and pancreatic neuroendocrine tumors in the United States
Orphanet Journal of Rare Diseases, 2024
2024Jonasch E, Song Y, Freimark J, Berman R, Nguyen H, Signorovitch J, Sundaram M
-
Incidence of pneumococcal disease in children ≤48 months old in the United States: 1998–2019
Vaccine, 2024
2024Mohanty S, Done N, Liu Q, Song Y, Wang T, Gaburo K, Sarpong EM, White M, Weaver JP, Signorovitch J, Weiss T
-
Contemporary outpatient management of patients with worsening heart failure with reduced ejection fraction: Clinical outcome results from the CHART-HF study
International Journal of Cardiology: Cardiovascular Risk and Prevention, 2024
2024Gaggin HK, Greene SJ, Zhou M, Lautsch D, Bash LD, Djatche L, Song Y, Signorovitch J, Stevenson AS, Blaustein RO, Butler J
-
Functional trajectories before and after loss of ambulation in Duchenne muscular dystrophy and implications for clinical trials
PLOS One, 2024
2024McDonald CM, Signorovitch J, Mercuri E, Niks EH, Wong B, Fillbrunn M, Sajeev G, Yim E, Dieye I, Miller D, Ward SJ, Goemans N
-
Meaningful changes in motor function in Duchenne muscular dystrophy (DMD): A multi-center study
PLOS One, 2024
2024Muntoni F, Signorovitch J, Sajeev G, Done N, Yao Z, Goemans N, McDonald C, Mercuri E, Niks EH, Wong B, Vandenborne K, Straub V, de Groot IJM, Tian C, Manzur A, Dieye I, Lane H, Ward SJ, Servais L
-
Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM
Future Oncology, 2024
2024Masarova L, Verstovsek S, Liu T, Rao S, Sajeev G, Fillbrunn M, Simpson R, Li W, Yang J, Lorier YL, Gorsh B, Signorovitch J
-
Assessing the Impact of Open-Label Designs in Patient-Reported Outcomes: Investigation in Oncology Clinical Trials
JNCI Cancer Spectrum, 2023
2023Lord-Bessen J, Signorovitch J, Yang M, Georgieva M, Roydhouse J
-
Disease-Free Survival as a Predictor of Overall Survival in Localized Renal Cell Carcinoma Following Initial Nephrectomy: A Retrospective Analysis of Surveillance, Epidemiology and End Results-Medicare Data
International Journal of Urology, 2023
2023Haas NB, Song Y, Rogerio JW, Zhang S, Carley C, Zhu J, Bhattacharya R, Signorovitch J, Sundaram M
-
Economic Burden of Acute Otitis Media, Pneumonia, and Invasive Pneumococcal Disease in Children in the United States after the Introduction of 13-Valent Pneumococcal Conjugate Vaccines During 2014-2018
BMC Health Services Research, 2023
2023Hu T, Song Y, Done N, Mohanty S, Liu Q, Sarpong EM, Lemus-Wirtz E, Signorovitch J, Weiss T
-
Epidemiology and Economic Burden of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma in the United States
Clinical Genitourinary Cancer, 2023
2023Jonasch E, Song Y, Freimark J, Berman R, Nguyen H, Signorovitch J, Sundaram M
-
Incidence of Non-Invasive All-Cause Pneumonia in Children in the United States before and after the Introduction of Pneumococcal Conjugate Vaccines: A Retrospective Claims Database Analysis
Pneumonia, 2023
2023Hu T, Sarpong EM, Song Y, Done N, Liu Q, Lemus-Wirtz E, Signorovitch J, Mohanty S, Weiss T
-
On the Double-Robustness and Semiparametric Efficiency of Matching-Adjusted Indirect Comparisons
Research Synthesis Methods, 2023
2023Cheng D, Tchetgen E, Signorovitch J
-
Patient Characteristics Associated with All-Cause Healthcare Costs of Alopecia Areata in the United States
Journal of Medical Economics, 2023
2023Gao W, Mostaghimi A, Gandhi K, Done N, Ray M, Signorovitch J, Swallow E, Carley C, Wang T, Sikirica V
-
Disease Progression Rates in Ambulatory Duchenne Muscular Dystrophy by Steroid Type, Patient Age and Functional Status
Journal of Comparative Effectiveness Research, 2023
2023McDonald CM, Marden JR, Shieh PB, Wong BL, Lane H, Zhang A, Nguyen H, Frean M, Trifillis P, Koladicz K, Signorovitch J
-
Functional and Clinical Outcomes Associated with Steroid Treatment among Non-Ambulatory Patients with Duchenne Muscular Dystrophy1
Journal of Neuromuscular Diseases, 2023
2023McDonald CM, Mayer OH, Hor KN, Miller D, Goemans N, Henricson EK, Marden JR, Freimark J, Lane H, Zhang A, Frean M, Trifillis P, Koladicz K, Signorovitch J
-
Evaluation of Disease-Free Survival as a Predictor of Overall Survival and Assessment of Real-World Burden of Disease Recurrence in Resected Early-Stage Non-Small Cell Lung Cancer
Journal of Managed Care & Specialty Pharmacy, 2023
2023West H, Hu X, Zhang S, Song Y, Chirovsky D, Gao C, Lerner A, Jiang A, Signorovitch J, Samkari A
-
Health-Related Quality of Life Instruments for Clinical Trials in AL Amyloidosis: Report from the Amyloidosis Forum HRQOL Working Group
Patient Related Outcome Measures, 2023
2023Rizio AA, White MK, D'Souza A, Hsu K, Schmitt P, Quock TP, Signorovitch J, Lousada I, Sanchorawala V
-
DMD Genotypes and Motor Function in Duchenne Muscular Dystrophy: A Multi-Institution Meta-Analysis with Implications for Clinical Trials
Neurology, 2023
2023Muntoni F, Signorovitch J, Sajeev G, Lane H, Jenkins M, Dieye I, Ward SJ, McDonald C, Goemans N, Niks EH, Wong B, Servais L, Straub V, Guglieri M, de Groot IJM, Chesshyre M, Tian C, Manzur AY, Mercuri E, Aartsma-Rus A
-
Longitudinal Assessment of Creatine Kinase, Creatine/Creatinine(Ratio), and Myostatin as Monitoring Biomarkers in Becker Muscular Dystrophy
Neurology, 2023
2023van de Velde NM, Koeks Z, Signorelli M, Verwey N, Overzier M, Bakker JA, Sajeev G, Signorovitch J, Ricotti V, Verschuuren J, Brown K, Spitali P, Niks EH
-
Matching-Adjusted Indirect Comparison (MAIC) Results Confirmed by Head-to-Head Trials: A Case Study in Psoriasis
The Journal of Dermatological Treatment, 2023
2023Signorovitch J, Diels J, Van Sanden S, Schubert A, Hassan F, Thilakarathne P, Ozturk B, Barthelmes N, Reich K
-
Treatment Patterns and Outcomes in Resected Early-Stage Non-Small Cell Lung Cancer: An Analysis of the Seer-Medicare Data
Clinical Lung Cancer, 2023
2023West H, Hu X, Zhang S, Song Y, Chirovsky D, Gao C, Lerner A, Jiang A, Signorovitch J, Samkari A
-
Disease burden and predictors associated with non-response to antihistamine-based therapy in chronic spontaneous urticaria
The World Allergy Organization Journal, 2023
2023Soong W, Patil D, Pivneva I, Signorovitch J, Wells MA, Balp MM, Kuruvilla M
-
Healthcare costs among patients with hematologic malignancies receiving allogeneic transplants: a US payer perspective
Blood Advances, 2023
2023Maziarz RT, Gergis U, Edwards ML, Song Y, Liu Q, Anderson A, Signorovitch JE, Manghani R, Simantov R, Shin H, Sivaraman S
-
Event-Free Survival as a Predictor of Overall Survival and Recurrence Burden of Patients with Non-Small Cell Lung Cancer Receiving Neoadjuvant Therapy
The Journal of Thoracic and Cardiovascular Surgery, 2023
2023Donington J, Hu X, Zhang S, Song Y, Arunachalam A, Chirovsky D, Gao C, Lerner A, Jiang A, Signorovitch J, Samkari A
-
Impact of choice of inhalers for asthma care on global carbon footprint and societal costs: a long-term economic evaluation
Journal of Medical Economics, 2022
2022Kponee-Shovein K, Marvel J, Ishikawa R, Choubey A, Kaur H, Ngom K, Fakih I, Swartz N, Schatzki T, Signorovitch J
-
Long-term treatment effects of inotersen on health-related quality of life in patients with hATTR amyloidosis with polyneuropathy: Analysis of the open-label extension of the NEURO-TTR trial
Muscle & Nerve, 2022
2022Karam C, Brown D, Yang M, Done N, Zhu JJ, Greatsinger A, Bozas A, Vera-Llonch M, Signorovitch J
-
Factors associated with increased health-related quality-of-life benefits in hereditary transthyretin amyloidosis polyneuropathy patients treated with inotersen
Muscle & Nerve, 2022
2022Karam C, Brown D, Yang M, Done N, Dieye I, Bozas A, Vera-Llonch M, Signorovitch J
-
PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials
BMC Cancer, 2022
2022Fillbrunn M, Signorovitch J, André F, Wang I, Lorenzo I, Ridolfi A, Park J, Dua A, Rugo HS
-
Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel versus Umbilical Cord Blood
Transplantation and Cellular Therapy, 2022
2022Lin C, Sajeev G, Stiff PJ, Brunstein CG, Cutler C, Sanz G, Lindemans CA, Rezvani AR, Hanna R, Koh LP, Maziarz RT, Hwang WYK, Song Y, Liu Q, Manghani R, Sivaraman S, Signorovitch J, Horwitz ME, Sung AD
-
Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data
Journal of Managed Care & Specialty Pharmacy, 2022
2022Sundaram M, Song Y, Rogerio JW, Zhang S, Bhattacharya R, Adejoro O, Carley C, Zhu J, Signorovitch J, Haas NB
-
Incidence of invasive pneumococcal disease in children with commercial insurance or Medicaid coverage in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018
BMC Public Health, 2022
2022Hu T, Song Y, Done N, Liu Q, Sarpong EM, Lemus-Wirtz E, Signorovitch J, Mohanty S, Weiss T
-
Healthcare Utilization and Costs Among US Adolescents With Alopecia Areata
Journal of Health Economics and Outcomes Research, 2022
2022Ray M, Swallow E, Gandhi K, Carley C, Sikirica V, Wang T, Done N, Signorovitch J, Mostaghimi A
-
Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use
Journal of Medical Economics, 2022
2022Proudman D, DeVito NC, Belinson S, Allo MA, Morris ED, Signorovitch J, Patel AK
-
Contemporary Outpatient Management of Patients with Worsening Heart Failure with Reduced Ejection Fraction: Rationale and Design of the CHART-HF Study
American Heart Journal, 2022
2022Greene SJ, Lautsch D, Gaggin HK, Djatche LM, Zhou M, Song Y, Signorovitch J, Stevenson AS, Blaustein RO, Butler J
-
A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment
Journal of Neuromuscular Diseases, 2022
2022Mitelman O, Abdel-Hamid HZ, Byrne BJ, Connolly AM, Heydemann P, Proud C, Shieh PB, Wagner KR, Dugar A, Santra S, Signorovitch J, Goemans N, investigators from the LNMRC Natural History study, McDonald CM, investigators from the CINRG Duchenne National History Study, Mercuri E, investigators from The DMD Italian Group, Mendell JR
-
Overall survival in the real-world and clinical trials: a case study validating external controls in advanced melanoma
Future Oncology, 2022
2022Signorovitch J, Moshyk A, Zhao J, Le TK, Burns L, Gooden K, Hamilton M
-
The Economic Burden of Recurrence in Triple-Negative Breast Cancer Among Working Age Patients in the United States
Advances in Therapy, 2022
2022Sieluk J, Song Y, Freimark J, Huang M, Haiderali A, Berman R, Wang T, Signorovitch J, Hirshfield KM
-
Carbon footprint and associated costs of asthma exacerbation care among UK adults
Journal of Medical Economics, 2022
2022Kponee-Shovein K, Marvel J, Ishikawa R, Choubey A, Kaur H, Thokala P, Ngom K, Fakih I, Schatzki T, Signorovitch J
-
Incidence of acute otitis media in children in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018
BMS Infectious Diseases, 2022
2022Hu T, Done N, Petigara T, Mohanty S, Song Y, Liu Q, Lemus-Wirtz E, Signorovitch J, Sarpong E, Weiss T
-
Predicting Clinical Remission of Chronic Urticaria Using Random Survival Forests: Machine Learning Applied to Real-World Data
Dermatology and Therapy, 2022
2022Pivneva I, Balp MM, Geissbühler Y, Severin T, Smeets S, Signorovitch J, Royer J, Liang Y, Cornwall T, Pan J, Danyliv A, McKenna SJ, Marsland AM, Soong W
-
Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19
JACC: Heart Failure, 2021
2021Bhatt AS, Jering KS, Vaduganathan M, Claggett BL, Cunningham JW, Rosenthal N, Signorovitch J, Thune JJ, Vardeny O, Solomon SD
-
Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis
Multiple Sclerosis Journal – Experimental, Translational and Clinical, 2021
2021Healy BC, Glanz BI, Swallow E, Signorovitch J, Hagan K, Silva D, Pelletier C, Chitnis T, Weiner H
-
Steroid switching in dystrophinopathy treatment: a US chart review of patient characteristics and clinical outcomes
Journal of Comparative Effectiveness Research, 2021
2021Marden JR, Santos C, Pfister B, Able R, Lane H, Somma M, Zhao J, Signorovitch J, Parsons J, Apkon S
-
Risk of Nephrolithiasis and Nephrocalcinosis in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study
Advances in Therapy, 2021
2021Ketteler M, Chen K, Gosmanova EO, Signorovitch J, Mu F, Young JA, Sherry N, Rejnmark L
-
A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?
Advances in Therapy, 2020
2020Zhang J, Li J, Ma Q, Yang H, Signorovitch J, Wu E
-
Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis
Journal of Comparative Effectiveness Research, 2020
2020Swallow E, Patterson-Lomba O, Yin L, Mehta R, Pelletier C, Kao D, Sheffield JK, Stonehouse T, Signorovitch J
-
Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial
Blood Advances, 2020
2020Schuster SJ, Maziarz RT, Rusch ES, Li J, Signorovitch JE, Romanov VV, Locke FL, Maloney DG
-
Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single, large care center
Journal of Comparative Effectiveness Research, 2020
2020Marden JR, Freimark J, Yao Z, Signorovitch J, Tian C, Wong BL
-
Prognostic factors for changes in the timed 4-stair climb in patients with Duchenne muscular dystrophy, and implications for measuring drug efficacy: A multi-institutional collaboration
PLOS One, 2020
2020Goemans N, Wong B, Van den Hauwe M, Signorovitch J, Sajeev G, Cox D, Landry J, Jenkins M, Dieye I, Yao Z, Hossain I, Ward SJ, Collaborative Trajectory Analysis Project (cTAP)
-
Suitability of external controls for drug evaluation in Duchenne muscular dystrophy
Neurology, 2020
2020Goemans N, Signorovitch J, Sajeev G, Yao Z, Gordish-Dressman H, McDonald CM, Vandenborne K, Miller D, Ward SJ, Mercuri E, investigators from PRO-DMD-01 study, CINRG DNHS, ImagingDMD, and The DMD Italian Group
-
An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA
Clinical Drug Investigation, 2020
2020Bensimon AG, Zhou ZY, Jenkins M, Song Y, Gao W, Signorovitch J, Krepler C, Scherrer E, Wang J, Aguiar-Ibáñez R
-
Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma
Current Medical Research and Opinion, 2020
2020Bensimon AG, Zhong Y, Swami U, Briggs A, Young J, Feng Y, Song Y, Signorovitch J, Adejoro O, Chakravarty A, Chen M, Perini RF, Geynisman DM
-
Suitability of natural history data for external controls in Duchenne muscular dystrophy
Neurology, 2020
2020Goemans N, Signorovitch J, Sajeev G, Yao Z, Gordish-Dressman H, McDonald CM, Vandenborne K, Miller D, Ward SJ, Mercuri E
-
Myocardial fibrosis and the effect of primary prophylactic defibrillator implantation in patients with non-ischemic systolic heart failure—DANISH-MRI
American Heart Journal, 2020
2020Elming MB, Hammer-Hansen S, Voges I, Nyktari E, Raja AA, Svendsen JH, Pehrson S, Signorovitch J, Køber L, Prasad SK, Thune JJ
-
Causal inference and adjustment for reference-arm risk in indirect treatment comparison meta-analysis
Journal of Comparative Effectiveness Research, 2020
2020Swallow E, Patterson-Lomba O, Ayyagari R, Pelletier C, Mehta R, Signorovitch J
-
Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States
Gynecologic Oncology, 2020
2020Muston D, Hettle R, Monberg M, McLaurin KK, Gao W, Swallow E, Zhang S, Kalemaj I, Signorovitch J, Moore K
-
Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial
Blood Advances, 2020
2020Maziarz RT, Schuster SJ, Romanov VV, Rusch ES, Li J, Signorovitch JE, Maloney DG, Locke FL
-
Deflazacort versus prednisone treatment for Duchenne muscular dystrophy: a meta-analysis of disease progression rates in recent multicenter clinical trials
Muscle & Nerve, 2020
2020McDonald CM, Sajeev G, Yao Z, McDonnell E, Elfring G, Souza M, Peltz SW, Darras BT, Shieh PB, Cox DA, Landry J, Signorovitch J, ACT DMD Study Group and the Tadalafil DMD Study Group
-
A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer
Pharmacoeconomics, 2020
2020Gao W, Muston D, Monberg M, McLaurin K, Hettle R, Szamreta E, Swallow E, Zhang S, Kalemaj I, Signorovitch J, McQueen RB
-
Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer
Journal of Medical Economics. 2019 Feb;22(2):140-150
2019Signorovitch J, Zhou Z, Ryan J, Anhorn R, Chawla A
-
Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy
PLOS One, September 3, 2019
2019Muntoni F, Domingos J, Manzur AY, Mayhew A, Guglieri M, The UK NorthStar Network, Sajeev G, Signorovitch J, Ward SJ
-
Validation of an ambient measurement system (AMS) for physical activities in a paediatric population
Journal of Medical Engineering & Technology, 2019
2019Varsanik JS, Kimmel ZM, Laforet GA, Ricotti V, Sajeev G, Signorovitch J, Quiroz JA, Chevalier TW
-
Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma
Clinical Therapeutics, 2019
2019Telford C, Kabadi SM, Abhyankar S, Song J, Signorovitch J, Zhao J, Yao Z
-
The effect of implantable cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic heart failure
EP Europace, 2019
2019Rørth R, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, Signorovitch J, Bruun NE, Eiskjær H, Hassager C, Svendsen JH, Høfsten DE, Torp-Pedersen C, Pehrson S, Køber L, Kristensen SL
-
Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America
Advances in Therapy, 2019
2019Muniz DQ, Ratto B, Yang H, Zhao J, Jenkins M, Signorovitch J, Dezzani L, Salman P, Medina ML, Lopera D, Lerzo G, Del Castillo C, Chacon M, Martin A, Campos-Gomez S
-
Comparative efficacy of first-line ceritinib and crizotinib in advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer: an adjusted indirect comparison with external controls
Current Medical Research and Opinion, 2019
2019Li J, Knoll S, Bocharova I, Tang W, Signorovitch J
-
Effectiveness of first-line treatments in metastatic squamous non-small-cell lung cancer
Current Oncology, 2019
2019Levy BP, J E Signorovitch JE, Yang H, Patterson-Lomba O, Xiang CQ, Parisi M
-
Risk Models for Prediction of Implantable Cardioverter-Defibrillator Benefit: Insights From the DANISH Trial
JACC: Heart Failure, 2019
2019Kristensen SL, Levy WC, Shadman R, Nielsen JC, Haarbo J, Videbæk L, Bruun NE, Eiskjær H, Wiggers H, Brandes A, Thøgersen AM, Hassager C, Svendsen JH, Høfsten DE, Torp-Pedersen C, Pehrson S, James Signorovitch J, Køber L, Thune JJ
-
Real-world durability of relapse rate reduction in patients with multiple sclerosis receiving fingolimod for up to 3 years: a retrospective US claims database analysis
Journal of the Neurological Sciences, 2019
2019Fox E, Vieira MC, Johnson K, Peeples M, Bensimon AG, Signorovitch J, Herrera V
-
Right Ventricular Dysfunction and the Effect of Defibrillator Implantation in Patients With Nonischemic Systolic Heart Failure
Circulation: Arrhythmia and Electrophysiology, 2019
2019Elming MB, Hammer-Hansen S, Voges I, Nyktari E, Raja AA, Svendsen JH, Pehrson S, Signorovitch J, Køber LV, Prasad SK, Thune JJ
-
Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure
Journal of Parenteral and Enteral Nutrition, 2019
2019Chen K, Mu F, Xie J, Kelkar SS, Olivier C, Signorovitch J, Jeppesen PB
-
Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison
Journal of the European Academy of Dermatology and Venereology, 2019
2019Bewley AP, Shear NH, Calzavara-Pinton PG, Hansen JB, Nyeland ME, Signorovitch J
-
Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States
Journal of Medical Economics, 2019
2019Bensimon AG, Zhou ZY, Jenkins M, Song Y, Gao W, Signorovitch J, Krepler C, Liu FX, Wang J, Aguiar-Ibáñez R
-
Real-world utilization of molecular diagnostic testing and matched drug therapies in the treatment of metastatic cancers
Journal of Medical Economics. 2018 Jun;21(6):543-552
2018Chawla A, Peeples M, Li N, Anhorn R, Ryan J, Signorovitch J
-
Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials
Value in Health. Jan 2018;21(1):1-8
2018Papp KA, Yang M, Sundaram M, Jarvis J, Betts KA, Bao Y, Signorovitch JE
-
Real-world persistence with fingolimod for the treatment of multiple sclerosis: A systematic review and meta-analysis
Journal of the Neurological Sciences. May 15 2018;388:168-174
2018Kantor D, Johnson K, Vieira MC, Signorovitch J, Li N, Gao W, Koo V, Duchesneau E, Herrera V
-
Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis
Current Medical Research and Opinion. Apr 23 2018:1-9
2018Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ
-
Number needed to treat and costs per responder among biologic treatments for moderate to severe psoriasis
Current Medical Research and Opinion. 2018 Jul;34(7):1325-1333
2018Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Wu EQ
-
Estimated Cost of Anticancer Therapy Directed by Comprehensive Genomic Profiling in a Single-Center Study
JCO Precision Oncology, November 2, 2018
2018Chawla A; Janku F; Wheler J; Miller V; Ryan J; Anhorn, R; Zhou Z; Signorovitch J
-
Impact of Hidradenitis Suppurativa on Work Loss, Indirect Costs and Income
British Journal of Dermatology, 2018
2018Tzellos T, Yang H, Mu F, Calimlim B, Signorovitch J
-
Epilepsy treatment patterns among patients with tuberous sclerosis complex
Journal of the Neurological Sciences. 2018 Aug 15;391:104-108
2018Song J, Swallow E, Said Q, Peeples M, Meiselbach M, Signorovitch J, Kohrman M, Korf B, Krueger D, Wong M, Sparagana S
-
Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small-Cell Lung Cancer: A Network Meta-Analysis
Advances in Therapy. 2018 Jul;35(7):1035-1048
2018Li J, Sasane M, Zhao J, García-Horton V, Zhang P, Ricculli ML, Zhou ZY, Signorovitch J
-
Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data
BMJ Open. 2018 Aug 17;8(8):e021642
2018Li J, Sasane M, Zhang J, Zhao J, Ricculli ML, Yao Z, Redhu S, Signorovitch J
-
Comparative efficacy of first-line ceritinib and crizotinib in advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer: an adjusted indirect comparison with external controls
Current Medical Research and Opinion. 2018 Oct 26:1-7
2018Li J, Knoll S, Bocharova I, Tang W, Signorovitch J
-
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States
2018 Oct;35(10):1564-1577
2018Kim S, Signorovitch JE, Yang H, Patterson-Lomba O, Xiang CQ, Ung B, Parisi M, Marshall JL
-
Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)
Circulation. 2018 Oct 2;138(14):1387-1398
2018Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, Cirino AL, Fox JC, Lakdawala NK, Ware JS, Caleshu CA, Helms AS, Colan SD, Girolami F1, Cecchi F, Seidman CE, Sajeev G, Signorovitch J, Green EM, Olivotto I
-
Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial
Cancer. 2018 Oct 15;124(20):4032-4043
2018Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, Brun A, Signorovitch JE, Makenbaeva D, Mekan S, Sy O, Weisel K, Richardson PG
-
Identifying a subpopulation with higher likelihoods of early response to treatment in a heterogeneous rare disease: a post hoc study of response to teduglutide for short bowel syndrome
Therapeutics and Clinical Risk Management. 2018 Jul 25;14:1267-1277
2018Chen KS, Xie J, Tang W, Zhao J, Jeppesen PB, Signorovitch JE
-
Patterns of Disease Monitoring and Treatment Among Patients With Tuberous Sclerosis Complex-related Angiomyolipomas
Urology. Jun 2017;104:110-114
2017Swallow E, King S, Song J, Peeples M, Signorovitch JE, Liu Z, Prestifilippo J, Frost M, Kohrman M, Korf B, Krueger D, Sparagana S
-
Indirect Comparisons: A Brief History and a Practical Look Forward
Decision Making in a World of Comparative Effectiveness Research
2017Signorovitch J, Zhang J
-
Comparative efficacy of long-acting beta2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis
International Journal of Chronic Obstructive Pulmonary Disease. 2017;12:367-381
2017Donohue JF, Betts KA, Du EX, Altman P, Goyal P, Keininger DL, Gruenberger JB, Signorovitch JE
-
Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure
Circulation. Nov 7 2017;136(19):1772-1780
2017Elming MB, Nielsen JC, Haarbo J, Videbæk L, Korup E, Signorovitch J, Olesen LL, Hildebrandt P, Steffensen FH, Bruun NE, Eiskjær H, Brandes A, Thøgersen AM, Gustafsson F, Egstrup K, Videbæk R, Hassager C, Svendsen JH, Høfsten DE, Torp-Pedersen C, Pehrson S, Køber L, Thune JJ
-
Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials
Journal of the American Academy of Dermatology. Dec 2017;77(6):1030-1037
2017Gordon KB, Betts KA, Sundaram M, Signorovitch JE, Li J, Xie M, Wu EQ, Okun MM
-
Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA
International Journal of Urology. Apr 2017;24(4):272-278
2017Pal SK, Signorovitch JE, Li N, Zichlin ML, Liu Z, Ghate SR, Perez JR, Vogelzang NJ
-
Can Matching-Adjusted Indirect Comparison Methods Mitigate Placebo Response Differences Among Patient Populations in Adjunctive Trials of Brivaracetam and Levetiracetam?
Cns Drugs. Oct 2017;31(10):899-910
2017Swallow E, Fang A, Signorovitch J, Plumb J, Borghs S
-
Effectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real world
Clinical and Experimental Rheumatology. Sep-Oct 2017;35(5):791-798
2017Yang M, Galebach PJ, Signorovitch JE, Garg V
-
Patterns of Disease Monitoring and Treatment Among Patients with Tuberous Sclerosis Complex-related (1)
Urology. Jun 2017;104:110-114
2017Swallow E, King S, Song J, Peeples M, Signorovitch JE, Liu Z, Prestifilippo J, Frost M, Kohrman M, Korf B, Krueger D, Sparagana S
-
Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US
Rheumatology and Therapy, 2016 Sep 15
2016Strand V, Husni E, Griffith J, Zhou ZY, Signorovitch J, Ganguli A
-
Association between time to progression and subsequent survival inceritinib-treated patients with advanced ALK-positive non-small-cell lung cancer
Current Medical Research and Opinion, 2016 11; 32(11): 1911-1918. e-pub ahead of print 2016/08/05; doi: 10.1080/03007995.2016.1220934
2016Liu G, Zhang J, Zhou ZY, Li J, Cai X, Signorovitch J
-
Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy
Neuromuscuarl Disorders, 2016 05. e-pub ahead of print 2016/07/18; doi: 10.1016/j.nmd.2016.05.016.
2016Mercuri E, Signorovitch J, Swallow E, Song J, Ward SJ.
-
Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US
Journal of Medical Economics, 2016 05; 19(5): 462-468
2016Pal SK, Jonasch E, Signorovitch JE, Reichmann WM, Li N, Liu Z, Perez JR, Vogelzang NJ
-
Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison
Journal of Comparative Effectiveness Research, 2016 03; 5(2): 129-139. e-pub ahead of print 2015/09/22
2016Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Mu F, Kim S, Noviello S, Signorovitch J.
-
Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison
Clinical Therapeutics, 2016 02; 38(2): 404-412. e-pub ahead of print 2016/02/04
2016Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Peeples M, Mu F, Ackerman P, Signorovitch J.
-
Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review
Current Medical Research and Opinion, Opin 2016 01; 32(4): 741-747
2016Vogelzang NJ, Pal SK, Signorovitch JE, Reichmann WM, Li N, Yang C, Liu Z, Perez JR, Jonasch E
-
Burden of illness among patients with fragile X syndrome (FXS): a Medicaid perspective
Current Medical Research and Opinion, Opin 2016 03; 32(3): 405-416. e-pub ahead of print 2015/11/14
2016Nazareth T, Li N, Marynchenko M, Zhou Z, Chopra P, Signorovitch J, Wu E, Ahmed S, Marvel J, Sasane R
-
Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular D(1)
PLOS ONE, 2016 Oct 13;11(10):e0164684
2016Goemans N, Vanden Hauwe M, Signorovitch J, Swallow E, Song J
-
Physician experiences and preferences in the treatment of HR+/HER2- metastatic breast cancer in the United States: a physician survey
Clinical Therapeutics, 2016 02; 5(2): 209-220
2016Lin PL, Hao Y, Xie J, Li N, Zhong Y, Zhou Z, Signorovitch JE, Wu EQ
-
Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection
J Comp Eff Res. 2015 Nov;4(6):593-605. doi: 10.2217/cer.15.33. Epub 2015 Jul 10.
2015Signorovitch JE, Betts KA, Yan Y, Sorg R, Li J, Behl AS, Kalsekar A.
-
Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response
Br J Dermatol. 2015 Feb;172(2):504-12. doi: 10.1111/bjd.13437. Epub 2015 Jan 21.
2015Signorovitch JE, Betts KA, Yan YS, LeReun C, Sundaram M, Wu EQ, Mulani P.
-
Assessment of income growth in patients with rheumatoid arthritis treated with anti-tumor necrosis factor therapy
Journal of Medical Economics, 2015
2015Bergman M, De G, Ganguli A, Signorovitch J, Bao Y
-
Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe
J Med Econ. 2014 Dec; 17(12):837-45
2014Campone M, Yang H, Faust E, Kageleiry A, Signorovitch JE, Zhang J, Gao H.
-
Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing’s disease
Eur J Endocrinol. 2014 Jul; 171(1):89-98
2014Webb SM, Ware JE, Forsythe A, Yang M, Badia X, Nelson LM, Signorovitch JE, McLeod L, Maldonado M, Zgliczynski W, de Block C, Portocarrero-Ortiz L, Gadelha M
-
Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational Studies
PLoS One. 2014 Dec 10;9(12):e114264
2014Heng DY, Signorovitch J, Swallow E, Li N, Zhong Y, Qin P, Zhuo DY, Wang X, Park J, Stergiopoulos S, Kollmannsberger C
-
Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review
Curr Med Res Opin. 2014 Apr; 30(4):537-45
2014Wong MK, Yang H, Signorovitch JE, Wang X, Liu Z, Liu NS, Qi CZ, George DJ.
-
Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment
Br J Dermatol. 2014 Dec; 171(6):1434-42
2014Kimball AB, Jemec GB, Yang M, Kageleiry A, Signorovitch JE, Okun MM, Gu Y, Wang K, Mulani P, Sundaram M
-
Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012
Curr Med Res Opin. 2014 Aug;30(8):1537-45
2014Swallow E, Zhang J, Thomason D, Tan RD, Kageleiry A, Signorovitch J
-
Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison
Exp Hematol Oncol. 2013 Dec 6;2(1):32
2013Signorovitch J, Swallow E, Kantor E, Wang X, Klimovsky J, Haas T, Devine B, Metrakos P
-
Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution
Pediatr Pulmonol. 2012 Jan;47(1):44-52. doi: 10.1002/ppul.21521. Epub 2011 Aug 3.
2012Sawicki G, Signorovitch J, Zhang J, Latremouille-Viau D, von Wartburg M, Wu EQ, Shi L
-
Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs
Diabetes, Obesity and Metabolism, November 2012
2012Signorovitch J, Macaulay D, Diener M, Yan Y, Wu EQ, Gruenberger J, Frier B
-
Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity
J Med Econ. 2012; 15(6):1078-87
2012Erder MH, Signorovitch JE, Setyawan J, Yang H, Parikh K, Betts KA, Xie J, Hodgkins P, Wu EQ
-
Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder
Pharmacoepidemiology and Drug Safety, 2012
2012Signorovitch J, Erder MH, Xie J, Sikirica V, Lu M, Hodgkins PS, Wu EQ
-
The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate-severe psoriasis
JAAD. 2011 May 24
2011Kimball AB, Yu AP, Signorovitch J, Xie J, Tsaneva M, Gupta SR, Bao Y, Mulani PM
-
Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life
Clin Drug Investig. 2011; 31(1):51-60
2011Papp K, Signorovitch J, Ramakrishnan K, Yu AP, Gupta S, Bao Y, Mulani P
-
Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes: a matching-adjusted indirect comparison of randomized trials
Clin Drug Investig. 2011;31(9):665-74. doi: 10.2165/11592490-000000000-00000.
2011Signorovitch J, Wu EQ, Swallow E, Kantor E, Fan L, Gruenberger J
-
Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors
Curr Med Res Opin. 2011 Jun;27(6):1089-96. Epub 2011 Mar 28. Erratum in: Curr Med Res Opin. 2011 Sep;27(9):1708.
2011Signorovitch J, Ramakrishnan K, Ben-Hamadi R, Yu AP, Wu EQ, Dworak H, Erder M
-
Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials
Curr Med Res Opin. 2011 Jun;27(6):1263-71. Epub 2011 Apr 28
2011Signorovitch J, Wu EQ, Betts K, Parikh K, Kantor E, Guo A, Bollu V, Williams D, Wei L, DeAngelo D
-
Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials
Dermatology. 2010;220(1):1-7. Epub 2009 Nov 19
2010Mease P, Signorovitch J, Yu A, Wu E, Gupta S, Bao Y, Mulani P
-
The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial
J Am Acad Dermatol. 2010 May;62(5):812-8. Epub 2010 Mar 9
2010Menter A, Augustin M, Signorovitch J, Yu A, Wu E, Gupta S, Bao Y, Mulani P
-
Cardiovascular and Economic Outcomes After Initiation of Atorvastatin versus Simvastatin in an Employed Population Stratified by Cardiovascular Risk
Am J Ther. 2010 Aug 27
2010Simpson R Jr, Signorovitch J, Ramakrishnan K, Ivanova J, Birnbaum H, Kuznik A
-
Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment
Pharmacoeconomics. 2010 Oct 1;28(10):935-45. doi: 10.2165/11538370-000000000-00000
2010Signorovitch J, Wu E, Yu A, Gerrits C, Kantor E, Bao Y, Gupta S, Mulani P
-
Benefit-risk analysis of adalimumab vs methotrexate and placebo in the treatment of moderate to severe psoriasis
J Am Acad Dermatol. 2010 Oct 6. [Epub ahead of print]
2010Reich K, Signorovitch J, Ramakrishnan K, Yu A, Wu EQ, Gupta S, Bao Y, Mulani P
-
Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension
Curr Med Res Opin. 2010 Apr; 26(4):849-60
2010Signorovitch J, Zhang J, Wu EQ, Latremouille-Viau D, Yu AP, Dastani HB, Kahler KH
-
Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin
Curr Med Res Opin. 2010 Feb; 26(2):355-63
2010Signorovitch J, Duh M, Sengupta A, Gu A, Grant R, Raut M, Mody S, Schein J, Fisher A, Ng D
-
Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population
Mayo Clin Proc. 2009 Dec;84(12):1065-72
2009Simpson R Jr, Signorovitch J, Birnbaum H, Ivanova J, Connolly C, Kidolezi Y, Kuznik A
-
June 2, 2023
-
May 31, 2024
-
June 6, 2024
-
April 25, 2024
-
December 6, 2023
-
December 1, 2023
-
December 7, 2022
-
September 14, 2022
-
March 29, 2022
-
June 4, 2021
-
January 25, 2021